Study of Hemostatic Biomarkers in Acute Ischemic Stroke by Clinical Subtype

Background We studied the usefulness of hemostatic biomarkers in assessing the pathology of thrombus formation, subtype diagnosis, prognosis in the acute phase of cerebral infarction, and differences between various hemostatic biomarkers. Methods Our study included 69 patients with acute cerebral in...

Full description

Saved in:
Bibliographic Details
Published in:Journal of stroke and cerebrovascular diseases 2012-07, Vol.21 (5), p.404-410
Main Authors: Hirano, Koji, MD, PhD, Takashima, Shutaro, MD, PhD, Dougu, Nobuhiro, MD, PhD, Taguchi, Yoshiharu, MD, PhD, Nukui, Takamasa, MD, PhD, Konishi, Hirohumi, MD, Toyoda, Shigeo, MD, Kitajima, Isao, MD, PhD, Tanaka, Kortaro, MD, PhD
Format: Article
Language:English
Subjects:
Antithrombin III - metabolism
Biomarkers
Biomarkers - blood
Cardiovascular
D-dimer
Female
Fibrin - metabolism
Fibrin Fibrinogen Degradation Products - metabolism
fibrin monomer complex
Fibrinogen - metabolism
Hemostasis
Humans
Intracranial Thrombosis - blood
ischemic stroke
Male
Neurology
Prognosis
soluble fibrin
Stroke - blood
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background We studied the usefulness of hemostatic biomarkers in assessing the pathology of thrombus formation, subtype diagnosis, prognosis in the acute phase of cerebral infarction, and differences between various hemostatic biomarkers. Methods Our study included 69 patients with acute cerebral infarction who had been hospitalized within 2 days of stroke onset. Fibrin monomer complex (FMC), soluble fibrin (SF), D-dimer, thrombin–antithrombin III complex, fibrinogen, antithrombin III, and fibrin/fibrinogen degradation products (FDPs) were assayed as hemostatic biomarkers on days 1, 2, 3, and 7 of hospitalization. Results In the cardioembolic (CE) stroke group, FMC and SF levels were significantly higher on days 1 and 2 of hospitalization, and D-dimer levels were significantly higher on day 1 of hospitalization, compared to the noncardioembolic (non-CE) stroke group. FDP levels were significantly higher at all times in the CE group compared to the non-CE group. Neither the National Institute of Health Stroke Scale (NIHSS) used during hospitalization nor the modified Rankin Scale (mRS) used at discharge found any significant correlations to hemostatic biomarkers, but the NIHSS score during hospitalization was significantly higher in the CE group than in the non-CE group. Conclusions Measurements of hemostatic biomarkers, such as FMC, SF, and D-dimer on the early stage of cerebral infarction are useful for distinguishing between CE and non-CE stroke.
ISSN:1052-3057
1532-8511
DOI:10.1016/j.jstrokecerebrovasdis.2011.08.013